• Oculis will present new Phase 2 ACUITY biomarker analyses of Privosegtor in optic neuritis on October 22, 2026, at ACTRIMS-ECTRIMS in Toronto.
• The analyses evaluate blood markers of nerve injury and inflammation to assess Privosegtor’s potential neuroprotective effects.
• Privosegtor received FDA Breakthrough Therapy and European Medicines Agency PRIME designations following the successful Phase 2 trial.
• PIONEER-1, the first of two registrational trials in optic neuritis, is enrolling patients with or without multiple sclerosis.
• Plans include an investigational new drug application for Privosegtor in acute multiple sclerosis relapses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200200OMX_____CNEWS_EN_GNW1001278760_en) on October 20, 2026, and is solely responsible for the information contained therein.